ImmutepIMMP
Market Cap: $333M
About: Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
Employees: 41
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
108% more call options, than puts
Call options by funds: $1.2M | Put options by funds: $577K
22% more funds holding
Funds holding: 23 [Q1] → 28 (+5) [Q2]
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0.03% less ownership
Funds ownership: 0.2% [Q1] → 0.17% (-0.03%) [Q2]
11% less capital invested
Capital invested by funds: $5.46M [Q1] → $4.84M (-$623K) [Q2]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Baird Joel Beatty 33% 1-year accuracy 2 / 6 met price target | 162%upside $6 | Outperform Maintained | 27 Jun 2024 |